Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hemispherx Biopharma
ClinicalTrials.gov Identifier:
NCT00035893
First received: May 6, 2002
Last updated: April 16, 2013
Last verified: April 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2006
  Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)